![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
https://orcid.org/0000-0001-9281-5415
References
- Dominick S, Hickey M, Chin J, Su HI. 2015. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systemic Reviews CD007245.
- Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. 2010. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. International Journal of Cancer 126:483–489.
- Philip S, Taylor AH, Konje JC, Habiba M. 2019. The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen. Journal of Obstetrics and Gynaecology 39:1117–1122.
- Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Joensuu H, et al. 2016. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncologica 55:188–192.
- World Health Organisation (WHO). 2015. Medical eligibility criteria for contraceptive use [Internet]. Department of Reproductive Health and Research, World Health Organisation; [cited 2019 Oct 23]. Available from: https://apps.who.int/iris/bitstream/handle/10665/172915/WHO_RHR_15.07_eng.pdf;jsessionid=49FA9C6C06D36DE5ED5B56899D90CA06?sequence=1